Intelligent bio solutions announces preliminary fiscal fourth quarter revenue with double-digit sequential and year-over-year growth and strong operational momentum

Company anticipates fiscal fourth quarter sequential and year-on-year revenue growth of approximately 16% company advanced efforts to secure u.s. fda 510(k) clearance for planned u.s. market entry and strengthened global readiness through system upgrades and localization new york, aug. 07, 2025 (globe newswire) -- intelligent bio solutions inc. (nasdaq: inbs) ("inbs" or the "company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced preliminary, unaudited revenue results and key operational highlights for the fiscal fourth quarter and full-year ended june 30, 2025. "fiscal 2025 represented a year of disciplined execution and strategic investment.
INBS Ratings Summary
INBS Quant Ranking